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There is no doubt that Guidelines preparation and update constitutes one of the pillars of the ESC, and groups of experts in the field from across Europe are commissioned to write and review documents according to a structured process that extends over a two-year period. This process finally involves around 100 experts and influences the care provided to millions of people worldwide. 2 In recent years guidelines from both sides of the Atlantic 3,4 have increasingly been criticized for the limited amount of evidence underlying many of their recommendations. Multiple systematic analyses have shown that a limited number (<15%) of the recommendations in European and American cardiovascular guidelines are supported by evidence from multiple randomized controlled trials (RCTs) and meta-analyses.
Although very relevant, the meaning of these findings can remain largely unclear as they lacked a detailed breakdown to where (e.g. therapeutic versus diagnostic recommendations) the suggested lack of evidence is most problematic, unexpected, or potentially solvable.
To know which paucities in the evidence base are problematic and where to focus improvement efforts to them, it is necessary to identify areas of recommendations not supported by high-quality evidence and identify the underlying reasons. To reveal where gaps exist in the current cardiovascular evidence base, and allow better interpretation of the evidence underlying recommendations, van Dijk and colleagues performed a really valuable work trying to identify which types of recommendations (e.g. therapeutic or diagnostic) and which recommended actions (e.g. pharmaceutical intervention or non-invasive imaging) are supported by which level of evidence (LoE) in the Guidelines of the ESC.
They observed that with a median of 128 recommendations per guideline, most recommendations were of class I (47.7%), followed by class II (44.7%) and only 7.6% class III. However, only 14.1% of the recommendations are supported by multiple RCTs or meta-analysis (LoE A). Moreover the evidence levels supporting recommendations vary widely per: by high-quality evidence. These shortcomings included fragmentation of the research enterprise (a lack in common goals, vision and collaboration), missing incentives to fill evidence gaps and potential conflicts of interests.
On the other side, RCTs are usually confined to patients of specific ages with single conditions. There will never be enough time, effort or funding to implement RCTs to address all clinical scenarios that confront physicians. Individual patients are unique and many differ from those enrolled in the RCTs on which the guidelines are based, but consistent deviation should be explained. Elderly individuals with multiple comorbid conditions, who constitute an increasing number of patients seen in clinical practice, are excluded from most RCTs. 5 This results in the common need to extrapolate guideline recommendations built on ideal patients to the real patients seen in practice, which has elevated cardiovascular registries to a higher level of prominence. Despite the imperfections of registry data, which are often derived from administrative information embedded in electronic health records and have the potential for confounding inherent in non-randomized databases, registries have the potential to confirm results of RCTs or to extend them to individuals with more complex, comorbid conditions. It is unlikely that there will ever be RCTs confirming that a routine blood sample should be performed as soon as possible in the suspicion of acute coronary syndrome (LoE C), or that a haemoglobin and white blood cell blood test and electrocardiogram should be performed in patients with symptoms of heart failure (LoE C), or that a multidisciplinary team is beneficial when making management decisions for patients with complex coronary artery disease or valvular heart disease (LoE C), or that parachutes can reduce the risk of injury (Figure 1 ). The primacy of these recommendations ensures that guidelines remain patient-centric and do not evolve to a just-the-facts recitation of data distilled from RCTs of tests, treatments and devices.
It should be understood that guidelines are not rules but are what the word implies -guides. Guidelines provide advice to practising physicians, clarify contemporary areas of consensus, but also of disagreement, improve standards and guide clinical decision-making for routine clinical practice. In all the preambles of ESC Guidelines it is pointed out that they have been developed to support healthcare professionals and cannot substitute for individual care and expertise. Health professionals are encouraged to take the Guidelines fully into account when exercising their clinical judgement, as well as in the determination and the implementation of preventive, diagnostic or therapeutic medical strategies. However, the Guidelines do not override in any way whatsoever the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient's health condition and in consultation with that patient and the patient's caregiver where appropriate and/or necessary.
So the paper from van Dijk and colleagues is very much appreciated and provides crucial points of discussion to a very important topic.
A final point: the authors criticize the current Preventive Guidelines 6 on the included topics on population-based intervention because the related recommendations do not provide therapeutic procedures, in their opinion. But these guidelines for the first time provide tools for healthcare professionals to promote population-based strategies in all settings, with the aim to integrate these into national or regional prevention frameworks and to translate these in locally delivered healthcare services, in line with the recommendations of the World Health Organization global status report on non-communicable diseases.
All these aspects are indeed open for a discussion that will certainly contribute to awareness in cardiologists on the basis of their best clinical practice.
Declaration of conflicting interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
